For cancer
Bevacizumab is mainly used to treat different types of cancer, alone or together with other anti-cancer medicines, to destroy cancer cells or slow down their growth.
- Bevacizumab belongs to a group of targeted therapies called monoclonal antibodies.
- It's called targeted therapy because it specifically acts on a protein called vascular endothelial growth factor (VEGF). This protein helps cancer cells grow a new blood supply.
- Targeting VEGF reduces the supply of oxygen and nutrients to the tumour. This can shrink the tumour or stop it growing.
For respiratory papillomatosis
Bevacizumab is also used to treat recurrent respiratory papillomatosis. This is a rare condition that causes small, wart-like growths (papillomas) in your airways, larynx and vocal cords. Bevacizumab is used as well as surgery and may help to:
- reduce the growth of these papillomas
- improve your voice quality, and
- increase the time between surgeries, helping to reduce the number of operations needed.
For eye problems
Bevacizumab is also used to treat some eye problems which cause loss of vision, such as ocular neovascularisation and exudative ocular angiopathy. Bevacizumab is injected directly into your eye by a healthcare provider and helps to slow vision loss.
Bevacizumab is a biological medicine
Unlike most other medicines that are made from synthetic or man-made chemicals, bevacizumab is made from living sources such as bacteria, yeast, or cells from animals and plants.
There are 2 brands of bevacizumab available in Aotearoa New Zealand
The original brand of bevacizumab is called Avastin. Vegzelma is a very close, but not identical, copy of Avastin. It's called a biosimilar medicine. Read more about biosimilar medicines.
From March 2025, Vegzelma, will be funded under a Special Authority, for people who meet the criteria. A special authority means your specialist will need to make an application to Pharmac (the government medicine funding agency) for approval before the medicine can be funded for you.